Brief: Bioarctic Says FDA Accepts Filing Of Leqembi Sbla For IV Maintenance Dosing
10/06/2024 24:39
June 9 (Reuters) - Bioarctic Ab BIOAb.ST :
* FDA ACCEPTS FILING OF LEQEMBI ® (LECANEMAB-IRMB) SBLA FOR
IV
MAINTENANCE DOSING FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE
* PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE IS SET
FOR
JANUARY 25, 2025
Source text for Eikon: ID:nWkr1F5S2x
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln